Peer-reviewed veterinary case report
Rivoceranib drug reduces growth of dog mammary tumors in lab tests
By Lee, Jeong-Ha et al.·Published in Anticancer research·2019·Department of Veterinary Clinical Science, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Antitumor Activity of Rivoceranib Against Canine Mammary Gland Tumor Cell Lines.
- Species:
- dog
Plain-English summary
A study found that rivoceranib, a new cancer treatment, can effectively reduce the growth and spread of mammary gland tumors in female dogs. When tested on tumor cells, rivoceranib significantly slowed down cell growth and caused more tumor cells to die. This treatment works by targeting a specific receptor involved in tumor blood supply, leading to a decrease in tumor activity. While this research is promising, it's important for dog owners to consult their veterinarian about the best treatment options for their pets with mammary tumors.
People also search for: dog mammary tumor treatment · rivoceranib for canine cancer · female dog breast cancer symptoms
Abstract
BACKGROUND/AIM: Canine mammary gland tumors (CMGTs) are the most common tumors in female dogs. Rivoceranib (also known as apatinib) is a novel anti-angiogenic tyrosine kinase inhibitor that selectively binds to vascular endothelial growth factor receptor-2 (VEGFR2). The aim of this study was to disclose the antitumor effects of rivoceranib on CMGT cell lines. MATERIALS AND METHODS: The direct effects of rivoceranib on CMGT cells in vitro were analyzed by cell proliferation and migration assays. Cell-cycle distribution and apoptotic ratio were analyzed by flow cytometry. Expression levels of phosphorylated VEGFR2 were evaluated by western blot analysis. RESULTS: Rivoceranib treatment significantly reduced the proliferation and migration of CMGT cells in a dose-dependent manner. Flow cytometry results revealed significant increases in G/Gphase arrest and apoptosis proportional to the drug concentration used. Rivoceranib reduced the level of phosphorylated VEGFR2. CONCLUSION: We confirm that rivoceranib exerts antitumor effects on CMGT cells by inhibiting biological functions.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31570442/